Posted by Michael Wonder on 19 Oct 2022
FDA grants fast track designation to Tvardi Therapeutics’ TTI-101 for hepatocellular carcinoma
19 October 2022 - Tvardi Therapeutics today announced that its lead product, TTI-101, has been granted fast track designation by the US FDA for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma.
TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3. STAT3 is a key regulatory protein which plays a critical role in the pathogenesis of hepatocellular carcinoma by initiating tumourigenesis as well as promoting an immunosuppressive tumour microenvironment.
